ACCELERON PHARMA INC's ticker is XLRN and the CUSIP is 00434H108. A total of 138 filers reported holding ACCELERON PHARMA INC in Q2 2016. The put-call ratio across all filers is 6.11 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $163,032,000 | +1473.1% | 947,310 | +1047.0% | 0.02% | +2100.0% |
| Q2 2021 | $10,364,000 | -52.2% | 82,588 | -48.3% | 0.00% | -75.0% |
| Q1 2021 | $21,662,000 | -49.3% | 159,738 | -52.1% | 0.00% | 0.0% |
| Q4 2020 | $42,706,000 | +198.7% | 333,800 | +162.7% | 0.00% | +33.3% |
| Q3 2020 | $14,297,000 | -32.0% | 127,050 | -42.5% | 0.00% | -50.0% |
| Q2 2020 | $21,037,000 | +7.2% | 220,819 | +1.2% | 0.01% | 0.0% |
| Q1 2020 | $19,617,000 | +200.0% | 218,288 | +77.0% | 0.01% | +200.0% |
| Q4 2019 | $6,539,000 | -14.8% | 123,328 | -36.5% | 0.00% | 0.0% |
| Q3 2019 | $7,679,000 | -53.7% | 194,367 | -51.9% | 0.00% | 0.0% |
| Q2 2019 | $16,590,000 | +308.5% | 403,854 | +363.1% | 0.00% | +100.0% |
| Q1 2019 | $4,061,000 | -78.1% | 87,200 | -79.5% | 0.00% | -85.7% |
| Q4 2018 | $18,568,000 | -10.5% | 426,354 | +17.6% | 0.01% | +16.7% |
| Q3 2018 | $20,756,000 | +6.7% | 362,671 | -9.5% | 0.01% | -14.3% |
| Q2 2018 | $19,452,000 | +254.1% | 400,900 | +185.3% | 0.01% | +250.0% |
| Q1 2018 | $5,494,000 | +44.5% | 140,500 | +56.8% | 0.00% | 0.0% |
| Q4 2017 | $3,802,000 | +77.8% | 89,600 | +56.4% | 0.00% | +100.0% |
| Q3 2017 | $2,138,000 | -35.2% | 57,300 | -47.2% | 0.00% | -50.0% |
| Q2 2017 | $3,297,000 | +128.5% | 108,500 | +99.1% | 0.00% | +100.0% |
| Q1 2017 | $1,443,000 | -41.3% | 54,500 | -43.5% | 0.00% | 0.0% |
| Q4 2016 | $2,460,000 | -36.2% | 96,401 | -9.5% | 0.00% | -50.0% |
| Q3 2016 | $3,854,000 | +153.7% | 106,500 | +138.3% | 0.00% | – |
| Q2 2016 | $1,519,000 | +116.4% | 44,700 | +68.0% | 0.00% | – |
| Q1 2016 | $702,000 | -90.5% | 26,600 | -82.5% | 0.00% | -100.0% |
| Q4 2015 | $7,420,000 | +43.9% | 152,182 | -26.5% | 0.00% | 0.0% |
| Q3 2015 | $5,157,000 | -6.6% | 207,100 | +18.7% | 0.00% | +50.0% |
| Q2 2015 | $5,519,000 | +45.7% | 174,419 | +75.3% | 0.00% | 0.0% |
| Q1 2015 | $3,787,000 | -19.5% | 99,500 | -17.6% | 0.00% | +100.0% |
| Q4 2014 | $4,706,000 | +139.4% | 120,786 | +85.7% | 0.00% | – |
| Q3 2014 | $1,966,000 | -6.7% | 65,044 | +4.8% | 0.00% | -100.0% |
| Q2 2014 | $2,108,000 | – | 62,047 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Darwin Global Management, Ltd. | 938,490 | $120,070,000 | 33.50% |
| Foresite Capital Management III, LLC | 108,630 | $13,898,000 | 16.15% |
| Octagon Capital Advisors LP | 112,363 | $14,376,000 | 4.98% |
| Artal Group S.A. | 1,400,000 | $179,116,000 | 3.84% |
| Avoro Capital Advisors LLC | 1,550,000 | $198,307,000 | 3.42% |
| Affinity Asset Advisors, LLC | 45,000 | $5,757,000 | 3.05% |
| NWI MANAGEMENT LP | 200,000 | $25,588,000 | 2.54% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 71,000 | $9,063,000 | 2.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 2,600,000 | $332,644,000 | 2.00% |
| Parkman Healthcare Partners LLC | 52,458 | $6,711,000 | 1.72% |